Awakn Life Sciences Corp. (AWKNF)
OTCMKTS
· Delayed Price · Currency is USD
0.0650
-0.0140 (-17.72%)
May 15, 2025, 4:00 PM EDT
Awakn Life Sciences Revenue
Awakn Life Sciences had revenue of 3.67K CAD in the quarter ending October 31, 2024, a decrease of -87.32%. This brings the company's revenue in the last twelve months to 57.16K, down -12.80% year-over-year. In the fiscal year ending January 31, 2024, Awakn Life Sciences had annual revenue of 87.37K.
Revenue (ttm)
57.16K CAD
Revenue Growth
-12.80%
P/S Ratio
67.78
Revenue / Employee
9.53K CAD
Employees
6
Market Cap
2.78M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jan 31, 2024 | 87.37K | - | - |
Jan 31, 2023 | - | - | - |
Jan 31, 2022 | 236.04K | - | - |
Jan 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAwakn Life Sciences News
- 24 days ago - Awakn Life Sciences Announces Shareholder Approval of Arrangement - Newsfile Corp
- 5 weeks ago - Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement - Newsfile Corp
- 2 months ago - Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc - Newsfile Corp
- 3 months ago - Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD - Newsfile Corp
- 4 months ago - Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder - Newsfile Corp
- 5 months ago - Awakn Life Sciences Announces Credit Facility - Newsfile Corp
- 5 months ago - Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc - Newsfile Corp
- 5 months ago - Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program - Newsfile Corp